78 results
8-K
EX-99.1
BTAX
Biostax Corp.
9 Jul 13
Other Events
12:00am
. Federal Government Agency issued Security Identification Access Badge. If we do not receive the above requested information in a timely manner … , attendees may be denied access.
A few days before the meeting, you may receive an email with a barcode generated by FDA’s Lobbyguard system. If you
DEFR14A
BTAX
Biostax Corp.
21 Oct 19
Revised proxy
2:40pm
or e-mail. We encourage you to access and review all of the important information contained in the Revised Proxy Statement.You do not have to take any … a Notice of Internet Availability of Proxy Materials (the “Notice”) to the Company’s shareholders. All shareholders will have the ability to access
8-K
EX-3.1
BTAX
Biostax Corp.
16 Apr 20
Immune Therapeutics, Inc. and Forte Biotechnology Intl Corp Sign Sub-Licensing Agreement for Animal Health Applications
4:12pm
to the suspension of access to in-person operations, access to professional advisors and other financial and operational concerns associated
10-K
2013 FY
EX-14.1
BTAX
Biostax Corp.
31 Mar 14
Annual report
12:00am
that information is released to the general public. Employees who have received or have access to confidential information should take care to keep … publicity and to ensure that all those with an interest in the Company will have equal access to information. All inquiries or calls from the press
NT 10-K
BTAX
Biostax Corp.
30 Mar 20
Notice of late annual filing
1:13pm
to the suspension of access to in-person operations, access to professional advisors and other financial and operational concerns associated with or caused
8-K
EX-10.1
2lkqwhpq8l6vy q1
12 Oct 22
Entry into a Material Definitive Agreement
8:49am
DEFR14A
5yb9olyy
5 Sep 19
Revised proxy
9:46am
8-K
EX-99.1
in7gawogqbpq6 ilqit
24 Oct 23
Amendments to Articles of Incorporation or Bylaws
9:00am
8-K
EX-99.1
trf07a yvhd
27 Apr 18
Other Events
9:00am
10-12G/A
EX-10.13
n2orn4v swuy52
25 Sep 13
Registration of securities (amended)
12:00am
8-K
EX-10.1
ea0z7spp
11 Jun 18
Entry into a Material Definitive Agreement
12:00am
8-K
EX-10.1
ukw6p1 klz9
20 Mar 20
Immune Therapeutics, Inc. to Collaborate with Cytocom, Inc. to Develop Therapies for COVID-19
11:43am
8-K
EX-99.1
t4p20
4 Dec 14
Other Events
12:00am
8-K
ct4zja8d766
14 May 20
Other Events
10:08am